 "AstraZeneca Pharma soars 20% on delisting plan")
AstraZeneca Pharma India has hit the upper circuit filter of 20% at Rs 1,113 on the National Stock Exchange (NSE), after its Sweden-based parent company AstraZeneca Pharmaceuticals AB suggested that it plans to delist company’s equity shares from the Indian stock exchanges.
The board of directors of AstraZeneca Pharma India is scheduled to meet on Wednesday March 05, 2014 to consider the delisting proposal.
On March 01, 2014, the company received a letter from its parent and promoter, proposing to make a voluntary delisting offer to the public shareholders of the company, AstraZeneca Pharma India said in a statement.
The pharmaceutical company’s shares are currently listed on the Bombay Stock Exchange (BSE), National Stock Exchange of India (NSE) and Bangalore Stock Exchange Limited (BgSE).
AstraZeneca Pharmaceuticals AB holds 18.75 million equity shares or 75% of the total paid-up share capital of the company.
A combined around 26,000 shares have already changed hands on the counter and there are pending buy orders for nearly 65,000 shares on the NSE and BSE at 0920 hours.
The board of directors of AstraZeneca Pharma India is scheduled to meet on Wednesday March 05, 2014 to consider the delisting proposal.
On March 01, 2014, the company received a letter from its parent and promoter, proposing to make a voluntary delisting offer to the public shareholders of the company, AstraZeneca Pharma India said in a statement.
The pharmaceutical company’s shares are currently listed on the Bombay Stock Exchange (BSE), National Stock Exchange of India (NSE) and Bangalore Stock Exchange Limited (BgSE).
AstraZeneca Pharmaceuticals AB holds 18.75 million equity shares or 75% of the total paid-up share capital of the company.
A combined around 26,000 shares have already changed hands on the counter and there are pending buy orders for nearly 65,000 shares on the NSE and BSE at 0920 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%